| Literature DB >> 29850510 |
Patrizia Di Gennaro1, Valentina Sabatini2,3, Silvia Fallarini4, Roberto Pagliarin3, Guido Sello3.
Abstract
The recombinant catalase-peroxidase HPI from E. coli was used as an alternative enzyme in polymerization reactions for the production of (-) epicatechin oligomers and their biological activity was characterized. The enzyme was prepared in two forms: a purified and an immobilized form. Both were tested for their activity in oxidative polymerization reactions, and their stability and reusability were assessed. The polymerization reactions were followed by SEC-HPLC analyses, and the substrate was completely converted into one or more polymerization products depending on the reactions conditions. Results showed that the utilized conditions allowed for the isolation of some oligomers of different molecular weight: the oligomers containing 6 and 7 units of epicatechin substrate are the heaviest ones. Epicatechin was also used in reactions catalyzed by HRP in the same reaction conditions for comparison. In addition, one selected oligomer obtained by HPI enzyme catalysis was shown to act as in vitro inhibitor of tumor cell growth, like one oligomer deriving from epicatechin by HRP catalysis. These data confirm that epicatechin oligomeric form is more effective than its monomer in biological activity and suggest the use of HPI as an alternative enzyme in reactions for the production of epicatechin oligomers.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29850510 PMCID: PMC5937512 DOI: 10.1155/2018/3828627
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Dimerization of pyrogallol catalyzed by peroxidases.
Specific activity of HPI on resin on pyrogallol at 4°C.a
| Time | Specific activity |
|---|---|
| 1 d | 2.0 |
| 31 d | 4.5 |
| 41 d | 5.4 |
| 58 d | 2.6 |
| 121 d | 3.2 |
a μmol min−1 mg−1.
Epicatechin consumed by immobilized HPI in different reaction conditions.
| Reaction conditions | H2O2 (mM) | Enzyme (mg/mL) | Consumed epicatechin |
|---|---|---|---|
| Epicatechin 3.44 mM + EtOH 5% | 15.5 | 0.00 | No reaction |
| Epicatechin 0.69 mM + EtOH 20% | 11.2 | 0.01 | >90% |
| Epicatechin 3.44 mM + EtOH 5% | 15.5 | 0.01 | >90% |
| Epicatechin 3.44 mM + EtOH 30% | 8.8 | 0.01 | >90% |
| Epicatechin 17.2 mM + EtOH 30% | 52.9 | 0.01 | >25% |
Epicatechin consumed by purified HPI.
| H2O2 additions | Consumed epicatechin |
|---|---|
| 0 [0.0 mM] | 0% |
| 1 [3.9 mM] | 31% |
| 2 [7.8 mM] | 31% |
| 3 [11.7 mM] | 33% |
| 4 [15.6 mM] | 48% |
| 5 [19.5 mM] | 48% |
| 6 [23.4 mM] | 50% |
| 7 [27.3 mM] | 50% |
| 8 [31.2 mM] | 57% |
| 9 [35.1 mM] | 57% |
MW of the obtained oligomers.
| Compound | Retention timea | Measured MWb | Calculated MWc | Unitsd | Enzyme |
|---|---|---|---|---|---|
| epicatechin | 10.17 | 331e | 1 | ||
| P1 | 6.80 | 2326 | 2038 | 7 | HRP |
| P2 | 7.33 | 1520 | 6f | HPI | |
| P3 | 7.32 | 1724 | 1529 | 6f | HRP |
| P4 | 6.94 | 1885 | 7f | HRP | |
| P5 | 6.95 | 1875 | 7f | HPI | |
| P6 | 6.89 | 1937 | 7 | HPI |
aMeasured using SEC-2 system. bCalculated using SEC-1 system. cFrom the correlation line. dNumber of epicatechin units. eCorrected weight using Maldi/SEC ratio. fFrom the compound that lost the bicyclic part.
Conditions of reaction utilized for the obtained oligomers.
| Compound | Conc. EPI | Enz. | EtOH | mLa |
|---|---|---|---|---|
| P1 | 3.44 mM | 1 mg HRP | 20% | 20 |
| P2b | 3.44 mM | 0.01 mg HPI | 5% | 1 |
| P3 | 3.44 mM | 0.01 mg HRP | 5% | 1 |
| P4 | 3.44 mM | 0.01 mg HRP | 5% | 20 |
| P5 | 0.69 mM | 0.05 mg HPI | 20% | 2.5 |
| P6c | 3.44 mM | 0.01 mg HPI | 5% | 1 |
aReaction volume. b3 mL of H2O2 added. c42 mL of H2O2 added.
Figure 2Fragmentation of epicatechin.
Figure 3Oligomers effects on A375 (a and b) and WM266-4 (c and d) proliferation. Cells were treated with increasing concentrations (0.1–10 μg/ml) of polymers A and B or EC for 3 (a and c) and 6 days (b and d). Cell proliferation was analysed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay and results were expressed as mean of percentage of the number of cells with respect to control cells. Data are shown as mean ± SEM. p < 0.05.
Figure 4Oligomers effects on A375 (a) and WM266-4 (b) cell cycle. Cells were treated (10 μg/ml) with polymers A and B or EC for 6 days and cell cycle was analysed by fluorescence-activated cell sorter (FACS). Results are expressed as percentage of the cell population in each phase. Data are shown as mean ± SEM (standard error of mean). p < 0.05.
Figure 5Oligomers effects on A375 (a) and WM266-4 (b) viability. Cells were treated with polymers A and B or EC (10 μg/ml) for 6 days and cell death was analysed by fluorescence-activated cell sorter (FACS). Results are expressed as percentage of apoptotic and late apoptotic/necrotic cells in all samples. Data are shown as mean ± SEM. p < 0.05. CAM− identifies apoptotic cells (Calcein-AMlow) and CAM− PI+ identifies late apoptotic/necrotic cells (Calcein-AMlow, propidium iodide treated).